SCHEMBL3725518

SCHEMBL3725518

Cc1ccc(-c2cc(-c3cccnc3)cc(NCCc3c[nH]c4ccccc34)n2)o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.52
CDK4 P11802 1/20 0.50
CCND1 P24385 1/20 0.50
CYP1A2 P05177 5/20 0.47
CYP3A4 P08684 5/20 0.47
CYP2D6 P10635 5/20 0.47
CYP2C19 P33261 5/20 0.47
CLK4 Q9HAZ1 5/20 0.47
ALDH1A1 P00352 5/20 0.47
USP2 O75604 4/20 0.47
HSD17B10 Q99714 3/20 0.47
CYP2C9 P11712 3/20 0.47
ALOX15 P16050 2/20 0.47
HTR6 P50406 3/20 0.46
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 1/20 0.46
HTR1A P08908 2/20 0.43
HTR2A P28223 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3721674 0.87 GBA1 (0.53) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL3716388 0.85 CDK4 (0.53) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL3721977 0.84 GBA1 (0.55) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL3726838 0.83 GBA1 (0.51) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL3720240 0.83 GBA1 (0.55) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL3721336 0.82 GBA1 (0.54) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL3721967 0.81 CYP1A2 (0.54) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL3715061 0.80 GBA1 (0.55) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL2240068 0.76 CDK4 (0.55) GBA1CDK4CCND1CYP1A2CYP3A4
SCHEMBL4771731 0.75 GBA1 (0.54) GBA1CDK4CCND1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK GBA1 3582/4885CDK4 1396/4885CCND1 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.